Differential Adverse Events Between TNF-α Inhibitors and IL-17 Axis Inhibitors for the Treatment of Spondyloarthritis

Antonelli, Maria; Khan, Muhammad Asim; Magrey, Marina

doi:10.1007/s40674-015-0022-7

Cited by 5 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several smaller studies of IL inhibitors in individual rheumatic diseases have demonstrated an increased risk of infections, which is consistent with our study . There have also been several systematic reviews addressing the efficacy and safety of IL-1 inhibition in rheumatoid arthritis with similar findings .…”

Section: Discussionsupporting

confidence: 91%

“…Several smaller studies of IL inhibitors in individual rheumatic diseases have demonstrated an increased risk of infections, which is consistent with our study. 10,111,112 There have also been several systematic reviews addressing the efficacy and safety of IL-1 inhibition in rheumatoid arthritis with similar findings. 18,113,114 These studies assessed the infection risk of IL-1 inhibition, but we believe our study is unique in assessing infection risk across all IL inhibitors and is more comprehensive.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors

et al. 2019

View full text Add to dashboard Cite

Key PointsQuestionWhat is the risk of serious infections, opportunistic infections, and cancer in patients with rheumatologic diseases treated with interleukin inhibitors?FindingsIn this systematic review and meta-analysis of 74 randomized clinical trials comprising 29 214 patients, pooled results suggest that risk of serious infections, opportunistic infections, and cancer is increased in patients with rheumatologic diseases who are treated with interleukin inhibitors compared with placebo.MeaningThis analysis suggests estimates of risk for infections and cancer associated with the use of interleukin inhibitors that can inform shared decision-making when patients and clinicians are contemplating the use of interleukin inhibitors for rheumatologic diseases.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 78%

Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Safety and tolerability may influence the selection of therapy for AS [ 1 , 5 ]. Secukinumab was generally well tolerated in clinical trials, with a tolerability profile consistent with that observed in patients with plaque psoriasis (Sect.…”

Section: Place Of Secukinumab In the Management Of Ankylosing Spondylmentioning

confidence: 99%

“…NSAIDs are the first-line recommended agents for the treatment of active AS [ 3 , 4 ]. For patients whose disease remains active despite conventional treatment with NSAIDs [ 3 , 4 ], the advent of tumour necrosis factor (TNF) inhibitors has revolutionized the treatment landscape [ 5 ]. However, some patients fail to respond adequately to TNF inhibitors or develop tolerability issues, and the efficacy of TNF inhibitors can wane over time.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Secukinumab: A Review in Ankylosing Spondylitis

Blair

2019

Drugs

View full text Add to dashboard Cite

Secukinumab (Cosentyx®), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). Subcutaneous secukinumab significantly improved the clinical signs and symptoms of AS versus placebo in three of four phase III trials. The benefits of secukinumab were generally seen regardless of whether patients had or had not received previous tumour necrosis factor (TNF) inhibitor therapy, and were sustained during longer-term (up to 5 years) treatment. Secukinumab was also associated with improvements in spinal mobility, physical function, health-related quality of life and work productivity in some of the trials. In MEASURE 1, secukinumab reduced inflammation in the sacroiliac joint, and slowed radiographic progression. Secukinumab was generally well tolerated during up to 5 years’ treatment; the most commonly reported adverse event was nasopharyngitis. In the minority of patients who developed anti-drug antibodies (ADAs), ADAs did not decrease efficacy or increase adverse events. In conclusion, secukinumab is an effective therapy for TNF inhibitor-naive patients with active AS, and provides a useful treatment option for patients who have an inadequate response to or are intolerant of TNF inhibitors.

show abstract

A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis

et al. 2018

View full text Add to dashboard Cite

show abstract

Differential Adverse Events Between TNF-α Inhibitors and IL-17 Axis Inhibitors for the Treatment of Spondyloarthritis

Cited by 5 publications

References 59 publications

Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors

Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors

Secukinumab: A Review in Ankylosing Spondylitis

A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis

Contact Info

Product

Resources

About